
Sign up to save your podcasts
Or
This week on BioTech Nation, Robert Blum, CEO of CytoKinetics, joins me to talk about the company’s decades-long mission to keep hearts beating stronger and longer. With one heart drug under FDA review and more in the pipeline, CytoKinetics is working to address the full spectrum of heart failure, from weak hearts to overactive ones, and even exploring muscle health beyond the heart to support healthy aging.
4.1
2929 ratings
This week on BioTech Nation, Robert Blum, CEO of CytoKinetics, joins me to talk about the company’s decades-long mission to keep hearts beating stronger and longer. With one heart drug under FDA review and more in the pipeline, CytoKinetics is working to address the full spectrum of heart failure, from weak hearts to overactive ones, and even exploring muscle health beyond the heart to support healthy aging.
6,133 Listeners
4,238 Listeners
32,299 Listeners
3,481 Listeners
22,089 Listeners
2,174 Listeners
26,469 Listeners
3,369 Listeners
6,696 Listeners
9,272 Listeners
318 Listeners
29 Listeners
15,335 Listeners
3,365 Listeners
1,175 Listeners